Naproxen sodium
SIGMA/M1275 - 98.0-102.0%
Synonym: (S)-6-Methoxy-α-methyl-2-naphthaleneacetic acid sodium salt
CAS Number: 26159-34-2
Empirical Formula (Hill Notation): C14H13NaO3
Molecular Weight: 252.24
EC Number: 247-486-2
MDL Number: MFCD00058507
Linear Formula: C14H13NaO3
Product Type: Chemical
| assay | 98.0-102.0% |
| biological source | synthetic (organic) |
| form | powder |
| InChI | 1S/C14H14O3.Na/c1-9(14(15 |
| InChI key | CDBRNDSHEYLDJV-FVGYRXGTSA |
| originator | Bayer |
| Quality Level | 200 ![]() |
| SMILES string | [Na+].COc1ccc2cc(ccc2c1)[ |
| solubility | water: 100 mg/mL, clear to slightly hazy, colorless to faintly yellow |
| Application: | Naproxen sodium has been used to evaluate the thermodynamics of biomolecular interaction with bovine and human serum albumin. It has also been used to evaluate its efficiency in reducing the response of spinal dorsal horn neurons to noxious knee joint rotation. |
| Biochem/physiol Actions: | Cyclooxygenase (Prostaglandin H synthase 1 and 2) inhibitor. |
| Biochem/physiol Actions: | Naproxen binds preferably to serum albumin. The S-enantiomer of naproxen is 28-fold more potential as an anti-inflammatory drug compared to the R-isomer. The R-isomer is found to be a liver toxin and causes gastrointestinal disorders. |
| Features and Benefits: | This compound was developed by Bayer . To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here . |
| General description: | Naproxen belongs to phenylacetic acid class of Non-steroidal anti-inflammatory drugs (NSAIDs). |
| Packaging: | 5, 25, 50 g in poly bottle |
| Symbol | ![]() GHS07,GHS08 |
| Signal word | Danger |
| Hazard statements | H302 - H360 |
| Precautionary statements | P201 - P301 + P312 + P330 - P308 + P313 |
| Hazard Codes | T |
| Risk Statements | 61-22 |
| Safety Statements | 53-45 |
| RIDADR | NONH for all modes of transport |
| WGK Germany | WGK 3 |
| Purity | 98.0-102.0% |
| UNSPSC | 12352200 |



